Oncolytics Biotech (ONCY) Restructuring Costs (2024 - 2025)
Oncolytics Biotech's (ONCY) quarterly Restructuring Costs came in at $860335.8 in Q3 2025, up 8.57% year-over-year from $792430.7 in Q3 2024, and up 8.57% quarter-over-quarter from $792430.7 in Q3 2024.
Powered by 
Analysis
Oncolytics Biotech (ONCY) Restructuring Costs (2024 - 2025) Analysis & Trends
Oncolytics Biotech (ONCY) has reported Restructuring Costs for 2 consecutive years, with $860335.8 the latest figure, recorded in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 206.70 Bn | 192.71 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 180.18 Bn | 177.00 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 131.45 Bn | 123.60 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 81.94 Bn | 73.95 Bn | 3.93 Bn |
| 5 | Argenx Se | 60.60 Bn | 55.42 Bn | 1.37 Bn |
| 6 | Moderna | 53.81 Bn | 48.67 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.46 Bn | 30.15 Bn | 992.69 Mn |
| 8 | Biogen | 31.82 Bn | 30.54 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 29.10 Bn | 29.10 Bn | 1.16 Mn |
| 10 | Oncolytics Biotech | 93.90 Mn | 93.90 Mn | - |